GEN Exclusives

More »

GEN News Highlights

More »
Aug 16, 2011

BMS Taps BAC to Develop Ligands for Adnectin Biotherapeutics

  • BAC inked a collaboration with Bristol-Myers Squibb (BMS) to generate affinity ligands for the purification and analysis of BMS’ Adnectins™ biologics. BAC will work to discover and develop custom ligands on its CaptureSelect platform.

    “Our CaptureSelect platform enables us to produce ligands that have high affinity and specificity for individual proteins and facilitates the generation of an exceptionally pure product in a single purification step,” comments Laurens Sierkstra, CEO of BAC. “We are delighted to collaborate with Bristol-Myers Squibb on the development of ligands for their Adnectin proteins. These custom ligands should simplify the purification process.”

    Derived from human fibronectin, Adnectins are engineered using BMS’ PROfusion™ technology to either block or stimulate the action of specific targets across a range of therapeutic areas. BMS acquired these compounds when it bought Adnexus Therapeutics in October 2007.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?